$ADAG News

HC Wainwright & Co. Reiterates Buy on Adagene, Maintains $7 Price Target

Adagene Highlights SAFEbody Pipeline, ADG138 Clinical Launch and 2027 Catalysts

Adagene to Participate in H.C. Wainwright 4th Annual Immune Cell Engager Virtual Conference

Adagene Announces NMPA Clearance of Investigational New Drug Application for ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager

China’s NMPA Approves Adagene’s IND Application For ADG138, Double-Masked HER2×CD3 Bispecific T Cell Engager Built On Proprietary SAFEbody Precision Masking Technology

Adagene Inc. (ADAG) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

HC Wainwright & Co. Reiterates Buy on Adagene, Maintains $7 Price Target

Adagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology

Third Arc Bio Selects First Lead Candidate Upon 2025 Amended Strategic License Deal With Adagene

Chardan Capital Initiates Coverage On Adagene with Buy Rating, Announces Price Target of $9

Adagene Achieves Milestone in Collaboration with Exelixis for Advancement of SAFEbody® Antibody-Drug Conjugate Candidates

Adagene to Participate in Three Upcoming Investor Conferences

Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates

Adagene H1 Adj. EPS $(0.20) Misses $(0.10) Estimate, Sales $1.620M

Adagene (ADAG) Upgraded to Buy: Here's What You Should Know

Are Medical Stocks Lagging Adagene (ADAG) This Year?

Adagene Spotlights ADG126 Strategy as Masked CTLA-4 Trial Advances in Colorectal Cancer

Adagene to Participate in Two Upcoming Investor Conferences

Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug’s Potential as a Backbone Combination Therapy for Multiple Tumor Types

Adagene's Muzastotug Triplet Regimens Show Superior Response Rates In HCC And MSS CRC, Highlighting Improved Anti-CTLA-4 Tumor-Targeting At AACR 2026